An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

[1]  D. Montefiori,et al.  Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.

[2]  J. Mascola,et al.  A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques , 2021, Nature Medicine.

[3]  J. Klingström,et al.  Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.

[4]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[5]  A. Borobia,et al.  Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.

[6]  L. Cervera,et al.  Characterization of HIV‐1 virus‐like particles and determination of Gag stoichiometry for different production platforms , 2021, Biotechnology and bioengineering.

[7]  R. Center,et al.  Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env , 2021, Vaccines.

[8]  B. He,et al.  Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates , 2021, Frontiers in Immunology.

[9]  S. Ferrari,et al.  Author contributions , 2021 .

[10]  M. Nussenzweig,et al.  Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates , 2020, Cell.

[11]  D. Irvine,et al.  Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo , 2020, Immunity.

[12]  P. Moore,et al.  Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles , 2020, Vaccines.

[13]  D. Baker,et al.  Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle , 2019, Nature Communications.

[14]  J. Blanco,et al.  Production of HIV-1-based virus-like particles for vaccination: achievements and limits , 2019, Applied Microbiology and Biotechnology.

[15]  Jerome H. Kim,et al.  Novel prime-boost vaccine strategies against HIV-1 , 2019, Expert review of vaccines.

[16]  D. Irvine,et al.  Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques , 2019, Nature.

[17]  C. Sorzano,et al.  A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses , 2019, Viruses.

[18]  Jason S McLellan,et al.  Structure-Based Vaccine Antigen Design. , 2019, Annual review of medicine.

[19]  A. Bolhassani,et al.  Induction of a robust humoral response using HIV-1 VLPMPER-V3as a novel candidate vaccine in BALB/c mice. , 2019, Current HIV research.

[20]  R. Paredes,et al.  Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant , 2018, PloS one.

[21]  Dong Soo Yun,et al.  Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes , 2018, Scientific Reports.

[22]  A. Chakraborty,et al.  The low spike density of HIV may have evolved because of the effects of T helper cell depletion on affinity maturation , 2018, PLoS computational biology.

[23]  K. Überla,et al.  Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines , 2018, Journal of Virology.

[24]  B. Clotet,et al.  Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target , 2017, Front. Immunol..

[25]  D. Montefiori,et al.  Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults , 2017, PloS one.

[26]  Daniel W. Kulp,et al.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. , 2017, Virology.

[27]  R. Wyatt,et al.  Dense Array of Spikes on HIV-1 Virion Particles , 2017, Journal of Virology.

[28]  P. Zhu,et al.  In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. , 2017, Vaccine.

[29]  Jordi Villà-Freixa,et al.  Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif , 2017, Scientific Reports.

[30]  Khuloud T. Al-Jamal,et al.  Investigating the effect of tumor vascularization on magnetic targeting in vivo using retrospective design of experiment , 2016, Biomaterials.

[31]  A. Collins.  IgG subclass co‐expression brings harmony to the quartet model of murine IgG function , 2016, Immunology and cell biology.

[32]  A. Jungbauer,et al.  Purification of HIV-1 gag virus-like particles and separation of other extracellular particles. , 2016, Journal of chromatography. A.

[33]  R. Wyatt,et al.  High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.

[34]  K. Überla,et al.  The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses. , 2016, Vaccine.

[35]  Joseph G. Jardine,et al.  HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen , 2016, Science.

[36]  Darrell J Irvine,et al.  Beyond antigens and adjuvants: formulating future vaccines. , 2016, The Journal of clinical investigation.

[37]  K. Überla,et al.  Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells , 2015, The Journal of Immunology.

[38]  John P. Moore,et al.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity , 2015, Retrovirology.

[39]  H. Liao,et al.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research , 2015, Journal of Virology.

[40]  Daniel W. Kulp,et al.  Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site , 2015, PLoS pathogens.

[41]  Dina N. Kovarik,et al.  Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA , 2014, PloS one.

[42]  Gregory J. Hardy,et al.  HIV-1 antibodies and vaccine antigen selectively interact with lipid domains. , 2014, Biochimica et biophysica acta.

[43]  U. Reichl,et al.  A flow-through chromatography process for influenza A and B virus purification. , 2014, Journal of virological methods.

[44]  B. Clotet,et al.  Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals , 2014, Retrovirology.

[45]  H. Liao,et al.  Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses , 2013, The Journal of Immunology.

[46]  A. Lux,et al.  Of Mice and Men: The Need for Humanized Mouse Models to Study Human IgG Activity in Vivo , 2012, Journal of Clinical Immunology.

[47]  B. Haynes,et al.  Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls , 2011, The Journal of Immunology.

[48]  B. Clotet,et al.  A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. , 2011, Vaccine.

[49]  Eric O Long,et al.  Signal transduction during activation and inhibition of natural killer cells. , 2010, Current protocols in immunology.

[50]  Pamela J. Bjorkman,et al.  Few and Far Between: How HIV May Be Evading Antibody Avidity , 2010, PLoS pathogens.

[51]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[52]  D. Engelman,et al.  Molecular dynamics studies of the transmembrane domain of gp41 from HIV-1. , 2009, Biochimica et biophysica acta.

[53]  David C Montefiori,et al.  Measuring HIV neutralization in a luciferase reporter gene assay. , 2009, Methods in molecular biology.

[54]  Marc C. Johnson,et al.  Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. , 2008, Cell host & microbe.

[55]  T. Kamala.  Hock immunization: a humane alternative to mouse footpad injections. , 2007, Journal of immunological methods.

[56]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[57]  A. Matsukawa,et al.  INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINS , 2004, Shock.

[58]  H. Schwarz,et al.  Analysis of Cd44-Containing Lipid Rafts , 1999, The Journal of cell biology.

[59]  Wei Chen,et al.  Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. , 1998, Journal of immunology.

[60]  M. Neuberger,et al.  Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. , 1998, Immunity.

[61]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.